Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EPS (Weighted Average and Diluted) (2021 - 2026)

Neuroone Medical Technologies filings provide 7 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.25 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 43.18% to -$0.25 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.35, a 40.68% increase, with the full-year FY2025 number at -$0.09, up 80.43% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.25 in Q1 2026 for Neuroone Medical Technologies, down from -$0.03 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q4 2024 to a low of -$0.44 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.11 (2024), compared with a mean of -$0.14.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 142.86% in 2024 and later plummeted 300.0% in 2025.
  • Neuroone Medical Technologies' EPS (Weighted Average and Diluted) stood at -$0.11 in 2022, then crashed by 31.14% to -$0.14 in 2023, then skyrocketed by 142.86% to $0.06 in 2024, then plummeted by 150.0% to -$0.03 in 2025, then plummeted by 733.33% to -$0.25 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.25 (Q1 2026), -$0.03 (Q4 2025), and -$0.04 (Q3 2025) per Business Quant data.